Industry ShowcaseUZEDY: An LAI With a Spectrum of Key Attributes for the Treatment of SchizophreniaSupported by Teva Pharmaceutical

Registration Options

Activity Date: 04/09/2024

Session Time and Location

The live session is complete.

Session Summary

This presentation establishes what makes UZEDY different from other LAIs, including a review of distinguishing pharmacokinetic and administration related features. Key efficacy and safety are reviewed along with the once-monthly and once-every-two-month dosing options for UZEDY.

Learning Objectives

Understand the role of UZEDY as a long-acting injectable (LAI) treatment option for schizophrenia
Discuss the flexible once-monthly and once-every-2-months dosing options of UZEDY
Review the attributes of UZEDY, including initiation without loading dose or oral supplementation

Faculty Information and Disclosures

Ilan Melnick, MD

View biographical information and disclosures

Continuing Education Credit and Disclosures

View AAPP's Privacy Policy

AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.

Questions? Contact AAPP.

The bookmark/discussion system is temporarily disabled. Please check back later.

Grant Support

This activity is supported by an educational grant from Teva Pharmaceutical Industries Ltd.

Meeting Essentials

Industry Showcase
UZEDY: An LAI With a Spectrum of Key Attributes for the Treatment of Schizophrenia
Supported by Teva Pharmaceutical

Registration Options

Session Time and Location

Session Summary

Grant Support